Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise
MT Newswires Live
Aug 28
Roivant Sciences (ROIV) said Thursday the FDA approved LISRAYA for adults with dermatomyositis, with the once-daily pill now available in the US, sending its shares up 1.5%.
The approval follows the Phase 3 VALOR trial, which showed improvements across disease activity, skin disease, muscle strength and physical function, alongside reduced steroid use.
Roivant said the approval provides a new treatment option for adults with dermatomyositis and is continuing to advance brepocitinib in non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.